PRC
ITCI

Pearl River Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Pearl River Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,047
Closed -$277K – 397
2024
Q2 		$277K Sell
4,047
-4,042
-50% -$280K 0.04% 365
2024
Q1 		$560K Buy
+8,089
New +$556K 0.09% 288

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pearl River Capital's ITCI Position: Q3 2024 in Review

Pearl River Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 4,047 shares — an estimated $277K sold.

Pearl River Capital first reported a position in ITCI in Q1 2024 and held it in 2 quarters. The position peaked at $560K in Q1 2024. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Pearl River Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Pearl River Capital sold 4,047 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $277K.
  • Pearl River Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 2 quarters.
  • Pearl River Capital's Intra-Cellular Therapies Inc. position peaked at $560K in Q1 2024.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Pearl River Capital's 13F filing for Q3 2024.